Seoul, South Korea – AI-driven rare disease diagnostics company Three Billion (KRX: 394800) has been selected as the first Asian partner for iHope, a global program dedicated to improving access to precision medicine for children with rare diseases. The partnership with Genetic Alliance, the organization operating iHope, marks a significant step in expanding the program’s reach into developing nations, according to a press release issued on March 5, 2026.
The iHope program, initially launched as a social contribution initiative by genomics leader Illumina, aims to provide whole genome sequencing (WGS) to pediatric patients with rare diseases in regions with limited healthcare resources. This allows for more accurate diagnoses and informed treatment plans. Three Billion’s selection recognizes its expertise in genetic diagnostics and its established presence in the Asian market. The company will leverage its AI-powered variant interpretation technology to enhance diagnostic efficiency and reduce the “diagnostic odyssey” faced by patients and families in underserved areas.
According to research cited by Three Billion, utilizing WGS as a primary diagnostic tool in low-income countries with limited resources can achieve a rare disease diagnosis rate exceeding 60%. Over 70% of confirmed cases see changes in treatment or management strategies as a result of the genomic insights gained. This underscores the potential of precision medicine to dramatically improve patient outcomes, even in challenging healthcare environments.
Expanding Access to Genomic Diagnostics
Three Billion’s role as iHope’s Asian partner will focus on providing diagnostic services for pediatric rare disease patients in developing countries. The company brings to the collaboration over 75 countries’ worth of experience in operating genetic testing services, combined with its proprietary AI-based technology for analyzing genomic variations. This technology is designed to accelerate the interpretation of WGS data, leading to faster and more accurate diagnoses.
“We are honored to be the first Asian partner of the iHope program and to contribute to the global effort of improving access to precision medicine for children with rare diseases,” said Geum Chang-won, CEO of Three Billion, in a statement. “Our AI-driven diagnostic capabilities will support reduce the diagnostic delays and uncertainties faced by patients and families in developing countries.”
iHope and the Global Precision Medicine Landscape
The iHope program is a key component of the broader movement towards global precision medicine, which seeks to tailor medical treatment to the individual characteristics of each patient, including their genetic makeup. Illumina’s initial support and Genetic Alliance’s ongoing management have positioned iHope as a leading initiative in this field. The program’s focus on underserved populations addresses a critical gap in healthcare equity, ensuring that children in resource-limited settings have access to the same advanced diagnostic tools as those in wealthier nations.
Three Billion’s participation in iHope builds upon its growing international presence. In December 2025, the company received an “Export Tower” award recognizing over $3 million in exports, demonstrating its increasing success in the global market. News1 reported on this achievement, highlighting the company’s global growth trajectory.
What to Watch Next
The immediate next step for Three Billion will be the implementation of its diagnostic services within the iHope framework, focusing on establishing a stable and reliable WGS-based precision diagnostics system. The company will work closely with Genetic Alliance and Illumina to ensure seamless integration and maximize the impact of the program. The success of this partnership could pave the way for further expansion of iHope into other regions and the development of new diagnostic solutions for rare diseases. The long-term implications of this collaboration extend beyond improved patient care, potentially fostering greater investment in genomic research and infrastructure in developing countries.
What are your thoughts on the potential of AI-driven diagnostics to address healthcare disparities? Share your comments below and help us continue the conversation.
